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ABSTRACT OF DISSERTATION

EVALUATING THE INCIDENCE OF MELANOMA AND LUNG CANCER
OF CURRENT AND FORMER ACTIVE-DUTY U.S. MILITARY
WHO WERE DEPLOYED IN SUPPORT OF
OPERATION ENDURING FREEDOM AND OPERATION IRAQI FREEDOM
The incidence of melanoma and lung cancer has been gradually increasing in the
United States over the past three decades with the reputed causes due to etiological and
environmental exposures, and tobacco usage. There has been concern that melanoma and
lung cancer incidence among military personnel may be associated with deployment to
environments with intense sun exposure and increased smoking rates due to posttraumatic stress disorder. The aim of this study was to examine associations between
deployment in support of Operation Enduring Freedom (OEF) or Operation Iraqi
Freedom (OIF), from 2001 through 2015, with subsequent melanoma and lung cancer
incidence. We conducted an incidence-density matched case-control study with incident
melanoma and lung cancer cases and their respective matched controls. Our cases were
individuals in the Armed Forces who were serving in the Army, Navy, Air Force, or
Marines during 2001 to 2015, and developed melanoma or lung cancer. For each case, 10
controls were randomly selected from others in the Armed Forces matched on age, sex,
branch of service, time in military and year of matching. Conditional logistic regression
was used to evaluate associations between deployment, number of deployments, and
cumulative time deployed, and melanoma risk. After adjusting for covariates with a
biological plausibility to either melanoma or lung cancer, we evaluated individuals who
had deployed compared to those who had not deployed were significantly protective to
odds of being diagnosed with melanoma or lung cancer. The dissertation further
evaluated incidence rates of melanoma and lung cancer between the different branches of
service, Army, Air Force, Marines and Navy, between the years 2002 to 2015. The
dissertation supports previous research that service members in the Air Force and Navy
are at an increased risk for melanoma.

KEYWORDS: U.S. Military, Melanoma, Lung Cancer, Operation Enduring Freedom,
Operation Iraqi Freedom
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CHAPTER 1. MELANOMA
Abstract
Purpose The incidence of melanoma has been gradually increasing in the United States
over the past three decades with the reputed cause due to increasing sun exposure and
occurrence of sunburns. There has been concern that melanoma incidence among military
personnel may be associated with deployment to environments with intense sun exposure.
The aim of this study was to examine associations between deployment in support of
Operation Enduring Freedom (OEF) or Operation Iraqi Freedom (OIF), from 2001
through 2015, with subsequent melanoma incidence.
Methods We conducted an incidence-density matched case-control study with 1,363
incident melanoma cancer cases and 13,630 matched controls. Our cases were individuals
in the Armed Forces who were serving in the Army, Navy, Air Force, or Marines during
2001 to 2015, and developed melanoma. For each case, 10 controls were randomly
selected from others in the Armed Forces matched on age, sex, branch of service, time in
military and year of matching. Conditional logistic regression was used to evaluate
associations between deployment, number of deployments, and cumulative time
deployed, and melanoma risk.
Results After adjusting for combat occupation, race, and year entered the service; those
individuals who had deployed had a 13% decreased odd of melanoma compared to those
who had not deployed (odds ratio [OR] 0.87; 95% confidence interval [95% CI] 0.770.99, p-value of 0.043). Active-Duty U.S. military who deployed once or more, compared
to those with zero deployments showed no significant association for melanoma cancer
1

risk. Cumulative days in deployment was stratified into two categories, 1-262 days and
262+ days deployed. Those individuals with cumulative 1+ days in deployment,
compared to those with zero cumulative days showed no association for melanoma
cancer risk. Lastly, having served in a combat role, whether in deployment status or not,
showed an increased melanoma risk across all branches of service.
Conclusion Having been deployed, the number of deployments, and the number of
deployment days were not associated with increased odds of having melanoma. In fact,
there was reduced melanoma risk associated with all categories of deployment. However,
military members serving in a combat role, regardless of deployment history, need to be
educated and trained on the hazards of occupational sun exposure. These service
members need to be given the proper guidance to protect, identify, and mitigate the
caustic effects of melanoma.

Keywords: melanoma; skin cancer; deployment; Army; Navy; Marines; Air Force

Introduction
According to the American Cancer Society, an estimated 96,480 new melanomas
cases (about 57,220 in men and 39,260 in women) were diagnosed in 2019 (1-4). Of the
7,230 estimated deaths related to melanoma of the skin in 2019, approximately 4,740
were men and 2,490 were women (5). While melanoma accounts for only 1% - 3% of all
types of skin cancer, it has the highest mortality rate amongst all cancers (4).
Demographically, melanoma is one of the most frequently diagnosed cancers in adults
2

ages 20 to 30 years old and is the main cause of cancer death in women 25 to 30 years old
(5). Non-Hispanic Whites (NHW) are more than 20 times at risk of developing melanoma
compared to African Americans (2-4). Overall, the lifetime risk of melanoma is 2.6% (1
in 38) for NHW, 0.1% (1 in 1,000) for blacks, and 0.6% (1 in 167) for Hispanics (2-4).
Categorically, melanoma has three well documented risks: ultraviolet exposure;
genetic predisposition; and immunosuppression (6-7). Ultraviolet exposure risk factors
include sun exposure, living in high altitudes, tanning/artificial UV, a history of severe
sunburn in childhood or adolescence, or even intermittent intense sun exposure (6-7).
Genetic predisposition can include family history, race, and other societal constructs (89). Immunosuppression has shown conflicting results as a key component in the
development of melanoma (10-12). The etiology connecting melanoma and patients with
immunosuppression is demonstrated by the association between dermal invasion of
melanoma and its effect on the production of key components for immunity (13-14).
As of December 2015, over 2.8 million U.S. military personnel were deployed
outside the continent of the United States (OCONUS) for all services combined - Army,
Navy, Marines, and Air Force – totaling approximately ten percent of the entire U.S.
military (15). Approximately 6,000 service members have died during deployment in
support of OIF and OEF; exposures during deployment may potentially lead to
subsequent morbidity and mortality (15-16).
Exposures in the context of day-to-day military operations during OIF and OEF,
have been documented and are currently being researched towards integrated care for
OEF/OIF veterans (17). According to U.S. Dept of Veteran Affairs (VA), currently there
are over twelve environmental, chemical, and endemic disease risk factors affecting
3

Veterans of OIF and OEF. These include sand, dust, and airborne particles, to
occupational hazards and infectious diseases (18-20).
Occupational sun exposure for military members has been documented as a risk
factor for melanoma and non-melanoma skin cancers (21). Previous work has shown that
early intervention and screening could play a pivotal role in the treatment and prevention
melanoma (22). The U.S. military has emphasized treating and screening high-risk
populations, to mitigate the risk of skin cancer among service members (23). Examples of
these efforts include banning of tanning beds and wide-spread communication campaigns
emphasizing the importance of hydration and applying sunscreen while performing work
and or reactional activities outdoors (23).
The U.S. military’s public health authorities have long-standing mandates for all
individuals to apply sunscreen and take other protective measures against harmful UV
rays (24). However, according to a survey of Soldiers deployed in these specific combat
zones, less than 30% reported regular sunscreen use, and were unprotected from harmful
UV rays at least 70% of the time during their normal work duties (25).
There is variation in sun exposure within the deployed Soldier population.
Combat arms military personnel do not always have the capability to avoid or limit their
sun exposure, and the context of their work prevents them from applying sunscreen. For
instance, at times the Soldier is required to actively engage obstacles with an extreme
amount of personal protective equipment, and sunscreen could be viewed as a nonessential item (25).
Previous studies have shown that ionizing radiation exposure could be a major
hazard for Soldiers who have deployed, in terms of developing melanoma. The VA has
4

purported that a majority of cancers associated with military service result from radiation
exposure (4). While the military has provided ample personal protective equipment, to
mitigate this exposure, compliance with properly donning the equipment is still unclear.
Those service members who work on nuclear reactors, medical facilities, nuclear
weapons, manufacturing and construction, security operations, and air transport
operations (in-flight) especially at high altitudes, are all susceptible to high levels of
ionizing radiation (26-28). Other studies have shown that the Air Force and Navy, have
higher incidence of melanoma compared to the other services with unadjusted incidence
rates for melanoma around 2.45 per 10,000 person-years (26-28). One suspected
etiological risk factor is the aforementioned cosmic ionizing radiation exposure, which is
directly correlated with increasing in altitude. Therefore, Soldiers with aviation-specific
occupations may have increased exposure compared to ground forces (29-30).

Materials and Methods
Data Source
A nested case-control study was conducted among Active-Duty personnel who
were serving in one of the Armed Forces branches: Army, Navy, Marines, or Air Force,
from 2001 through 2015. The data were ascertained from the Armed Forces Health
Surveillance Division (AFHSD) who extracted them from the Defense Medical
Surveillance System (DMSS), and the Department of Defense (DoD) Automated Central
Tumor Registry Database. Deployment data came from AFHSD, United States Army
Special Operations Command (USASOC)-Human Resources Command, Marine Corps
5

Manpower, and Reserve Affairs. Occupational and demographic data for all study
subjects was ascertained from DMDC (Defense Manpower Data Center) databases.
Case Ascertainment
Cancer cases were identified using International Classification of Diseases-9
(ICD-9) diagnosis codes for cancer selection (Melanoma / 172.x / Malignant melanoma
of the skin) and discharge codes noted in the DoD inpatient and outpatient medical
records (DMSS). ICD-03 codes from tumor registry data and pathology reports were also
used to identify cases. Diagnostic codes corresponding to notations of cancer in
remission, relapse, or metastatic were utilized to confirm cases, but were not used to
identify cases – only the initial diagnosis of cancer was included in the case definition.
Cases were selected utilizing these criteria:
1) Those identified in the medical record and validated by the tumor registry data
2) Those identified in the medical record and not validated using tumor registry data
3) Those identified in the tumor registry, though not necessarily in the medical
record data.
To assign case status using DoD medical records, the AFHSD developed
definitions for surveillance purposes. Primary cancers were defined as one hospitalization
with any of the defining diagnoses of melanoma in the primary diagnostic position or one
hospitalization with a V-code indicating a radiotherapy, chemotherapy, or
immunotherapy treatment procedure in the primary diagnostic position. For any
individuals who constituted a case, the incidence date was defined as the date of the first
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hospitalization or outpatient medical encounter that includes a defining diagnosis for
melanoma.
An individual could be considered an incident case only once. Individuals with
diagnoses of prior cancers (regardless of type/location) in the medical record were
excluded from the study population. Analyses of solid cancers included only invasive
tumors; in-situ tumors were excluded.
In our primary analysis, cases were defined using medical records, without any
validation from the registry and/or pathology reports. A second set of analyses were
restricted to cases identified in the medical record and validated by either cancer registry
data or pathology reports. A final set of analyses were restricted to only those cases
obtained from the tumor registries. Cases consist of both genders, all races reported, and
ages ranging from 18 to 65 years old.
Control Ascertainment
Risk-set sampling was used to select controls. Details on risk-set sampling have
been published elsewhere (31-32). In brief, we performed longitudinal sampling of
controls through a follow-up period whereby controls were selected from the population
at risk of the cancer at the time a case is diagnosed. Ten control subjects were randomly
selected from each case’s corresponding risk sets as of date of initial cancer diagnoses
while matching on age (±5 years), gender, branch of service, and time in service. Risk
sets were identified using DoD/DMDC demographic data.

7

Study Design / Exposure Assessment
Once all cases and controls were identified for each of the three analyses, the
DMDC deployment database was queried using a roster of the entire study population
(cancer cases and corresponding controls) including personal identifiers, but not a
case/control status indicator.
The following deployment-related information was ascertained:
(1) Ever/never deployment status;
(2) Number of deployments;
(3) Number of days deployed based upon the start and end date of each
deployment, at any time greater than the minimum empirical latency period.
Exposure status was abstracted for the five assumed latent periods: 0, 1, 4, 8, and 10
years. For example, assuming an eight-year empirical latency period between exposure
and cancer diagnosis, the inquiry ascertained data on deployment history between the
START of OEF in the Fall of 2001, and January 10, 2004, for a case diagnosed on
January 10, 2012, and the corresponding matched controls. All deployments after January
10, 2004, were disregarded. Covariate information to be evaluated as potential
confounders, independent risk factors, and effect modifiers included race, smoking status
(smoker versus non-smoker), receiving cancer screening (yes versus no), number of
immunizations, and year of entry into the service.
Statistical Analysis
Descriptive statistics are presented as frequencies and percentages. Differences in
baseline characteristics between cancer cases and controls were assessed using primarily
8

Chi-square tests of two independent proportions and univariate conditional logistic
regression. Student’s t test, and univariate logistic regression were used to compare
continuous variables between cases and controls. All continuous variables, regardless of
distribution, were evaluated with parametric testing due to our robust sample size.
Several races and ethnicities were noted for the cases and controls, however due to low
number of participants in certain categories only three categories were used to analyze
the association between race and melanoma (NHW – ref, Black, and Other).
Our unadjusted conditional logistic regression models were based on predicting
the conditional log odds of cancer diagnosis by our three main variables for exposure:
1. deployment (ever versus never); 2. number of deployments; 3. cumulative deployed
time (days). Additionally, we evaluated odds ratios by race/ethnicity (White, Black, and
Other), smoking history (yes, no), special operations force personnel (yes, no), combat
occupation (yes, no), and year entered the Armed Forces Active-Duty status. The three
exposure variables were analyzed using conditional logistic regression while adjusting for
the following covariates: combat occupation (y vs n), race/ethnicity, and year entered
Active-Duty service. Variables with a statistically significant p-value (<0.05), and CI
without 1.0, and those covariates that have a biologically plausible association with our
outcome of interest were included in the models.
We estimated of the association between deployment (and other potential
explanatory variables) and odds of cancer diagnosis by using multivariable conditional
logistic regression. Risk comparison between cases and controls was presented as odds
ratios (OR) and 95% confidence intervals (95% CI) as well as calculated p-values. The
linearity of the exposure-responses between log odds of cancer and continuously
9

distributed variables were examined by creating indicator variables based on selected
categories. The risk variable, ‘number of deployments’ was categorized into three
categories: 0 deployments; 1 deployment; 2-9 deployments and total time deployed was
also categorized into three categories: 0 days deployed; 1 – 262 days deployed; and 263+
days deployed. Wald test p-values less than 0.05 were considered evidence of statistical
significance.
To assess the association between latency of primary exposure to date of
diagnosis, all three of our primary exposure variables and others that are associated with
risk for melanoma were evaluated in an unadjusted conditional logistic regression model
with corresponding ORs and 95% CI. All categorical variables were No vs Yes, and our
two exposure variables for number of deployments and cumulative years deployed were
each evaluated as continuous.

Results
The study included 1,363 melanoma cancer cases and 13,630 matched controls.
Baseline descriptive statistics (zero latency years) for cases and controls are presented in
Table 1.1. Although the cases were age-matched to their controls (+5 years), the mean
age of cases was 35.3 years and the mean age of the controls was 34.6 years, which was a
statistically significant difference because of the large size of the study (p=0.002). But
essentially the ages of the cases and controls were very similar. Almost twice as many of
the cases (8.9%) had served in a combat occupation, compared to their controls (4.9%);
this was a statistically significant difference (p <0.0001). The remaining characteristics
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used for matching were not statistically significantly different between cases and
controls.
Table 1.2 presents univariate conditional logistic regression results from our three
exposures of interest and potential confounders. The odds of developing melanoma
among those deployed was 12% less than those who had not deployed (OR=0.88, 95%CI
0.77-0.99, p-value 0.038). Individuals who were deployed once had a 13% decrease in
the odds of developing melanoma compared to individuals with zero deployments, (OR
0.87, 95%CI 0.75-0.99, p-value 0.047) and individuals deployed two or more times had
an 11% decrease in the odds of developing melanoma. Likewise, service members who
deployed for 1-262 days had a decreased odds of melanoma compared to those who did
not deploy at all (OR= 0.89, 95%CI 0.77-1.03, p-value 0.610), though this was not
statistically significant. Similarly, service members who deployed 263 days or more had a
decreased odds of melanoma compared to those who did not deploy at all (OR=0.82,
95%CI 0.72-1.01, p-value 0.211).
The risk of developing melanoma clearly differs by race; compared to NHWs:
Blacks had an OR of 0.03 (95%CI 0.01-0.05, p-value <.001) and Other an OR of 0.27
(95%CI 0.22 - 0.33, p-value <.001). Service members who were assigned to a combat
arms unit (Combat Occupation) had a 96% increase in the odds of diagnosis for
melanoma, compared to those who were not assigned to a combat role (OR 1.96, 95%CI
1.59-2.42, p-value<.001). Those individuals who entered one of the services between the
years 1996-2015, respectively had a 25-28% decrease in odds of melanoma, compared to
those who entered service between the years of 1964 – 1988, with associated p-values of
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<0.001. We found no association with risk of melanoma and those individuals who either
smoked or were serving in the Special Forces.
In our multiple conditional logistic regression model (Table 1.3) we evaluated
each of the three deployment variables in separate models with the following covariates:
combat occupation (yes vs no), race (white, black, other), and year the individual joined
the military. These three covariates were statistically significant in our unadjusted model
and held their significance in our final model. Service members who deployed versus
those who did not deploy demonstrated 13% decreased odds for melanoma (OR 0.87,
95%CI 0.77 - 0.99, p-value 0.043), adjusting for combat occupation, race, and year entry
to service. For those individuals who deployed once or more, compared to those who had
never deployed presented a non-significant association for the odds of melanoma. When
comparing one deployment to zero, (OR 0.87, 95%CI 0.75 - 1.00, p-value 0.054) it
dropped its value as being significant, when adjusted for the other covariates. Service
members with two or more deployments showed no significant association with odds of
melanoma, consistent with our unadjusted modeling (OR 0.85, 95%CI 0.72 - 1.01, pvalue 0.069). Cumulative days deployed, when compared to those with zero days for
deployment, showed no significant association for either category 1 – 262 days deployed
(OR 0.89, 95%CI 0.77-1.03, p-value 0.610) and 263+ days deployed (OR 0.82, 95% CI
0.72-1.01, p-value 0.211) when adjusting for other covariates.
Those service members assigned to a combat occupation had a 46% increase in
odds of being diagnosed with melanoma (OR 1.46, 95% CI 1.17 - 1.81, p-value <0.001)
after adjusting for all other covariates. The odds ratio for combat status had the greatest
change in overall OR from unadjusted to adjusted, 1.96 to 1.46. We further evaluated
12

combat occupation as a risk factor for melanoma by the number of deployments, number
of days of deployment, and branch of service (Tables1.5 and 1.6). Additionally, the odds
ratios for the exposure variables were adjusted by race.
With respect to latency periods, we evaluated zero, one, four, eight, and ten years
from date of diagnosis. Using an unadjusted conditional logistic regression, we evaluated
all exposure variables and several covariates we felt were impactful to the study. With
respect to our exposure variables, none showed any association to risk of melanoma,
except for the following two: 1. Deployed Years – 1 year latency – showed for every oneyear deployed with respect to one year of latency, had 11% decrease in the odds of
melanoma (OR 0.89, 95% CI 0.80-0.99). 2. Those individuals who had not deployed vs
those who had deployed, with respect to zero years latency, had a 14% increase in odds
of melanoma, which was demonstrated in our unadjusted conditional logistic regression
model (OR 1.14, 95% CI 1.01-1.30).
Of the covariates of interest, only combat occupation showed any association to
risk of melanoma and held its significance across all latency years evaluated. Those
individuals serving in a service and support roles, compared to those serving in a
combative function, had an approximate 50% decrease in the odds of melanoma
regardless of latency year. Neither smoking nor special forces operatives demonstrated
any association with odds of melanoma, regardless of latency year.

Discussion
Risk of melanoma has been attributed to the synergistic interaction between
genetic factors and sunlight exposure (33-34). Specifically, history of sunburns and
13

intermittent sun exposure have been postulated as primary risk factors for melanoma (3536). Sunburns and their severity are influenced by the individual’s melanin as it
suppresses ultraviolet (UV)-induced damage in human skin (37). NHWs have higher
incidence of sunburns compared to African Americans (AA) and Hispanics (38). It is
believed that intense periods of exposure to UV radiation increase the risk for developing
melanoma to a greater extent than does chronic cumulative UV radiation exposure (39).
Geographically, over 70% of melanomas are diagnosed in regions that receive
intermittent sun exposure (35). Our study showed that NHWs in the military have an
increased odds for diagnosis of melanoma, when compared to AA and members of other
racial minority groups. Additionally, our results show a protective association with those
who were deployed in regions that have higher cumulative UV radiation exposure,
compared to those who were non-deployed and were in regions that have an increase in
intermittent sunlight exposure. Of all the unmatched variables race was by far the most
associated with melanoma risk. The proportion of the races is differently distributed
across the exposure categories; therefore, we feel it necessary to treat race as a
confounder in this study.
One explanation for the negative association between deployment in OEF/OIF
and melanoma is due to Army regulations mandating limited outdoors activity across the
DoD operational bases. Per Army and other DoD regulations (40-41), individuals
deployed to areas with heat indexes exceeding established thresholds (40-41), general
orders were enacted to restrict all outside movement during these daytime hours and
serious consequence for any unit or individual conducting training or physical fitness (4244). These mandates could have resulted in reduced exposure to harmful UV radiation.
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Conversely, those individuals who were not deployed and remained CONUS kept their
same training regime and even recreational activities, thereby increasing their overall UV
sun exposure (46-48).
Apart from race, combat status showed a strong association with the odds of being
diagnosed for melanoma. When we further examined combat status, the odds of
melanoma decreased from 1.96 to 1.47 when adjusted for race. We can partially attribute
this decrease in odds ratio to the distribution of race in combat status, where 84% of the
Soldiers in combat status were white while only 64% in non-combat roles were white.
Additionally, these individuals by nature of their role and responsibilities – regardless of
deployment status – have a higher exposure to UV rays, and cosmic radiation. Different
maneuvers, patrols, convoys, and wartime engagements are all generally performed
outdoors, in austere environments, and under intense situations where applying sunscreen
or wearing lighter-colored clothing might not be a priority (47).
Our study is not without limitations, we do not know about other major risk
factors for melanoma, specifically history of UV exposure or sunburns, which both are
established components of developing melanoma later in life. Additionally, we have no
information regarding specific job duties and risk of occupational hazards (i.e., chemical,
radiation, infantry vs non-infantry) Lastly, we have no data as to where specifically each
Soldier was deployed (corresponding longitude and latitude) or for how long (duration of
exposure). Lastly, there is always a possibility of misclassification and misdiagnoses.
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Conclusion
While matching for age, sex, branch of service, time in military, and year of
matching, and adjusting for race and year of entry into the service, our study did not find
an increased melanoma risk for SM who were deployed to Operation Enduring Freedom
(OEF) or Operation Iraqi Freedom (OIF), from 2001 through 2015. We also did not find
increased melanoma risk by deployment status latency periods of 1, 4, 8, or 10 years. We
did find that SM in combat roles had increased risk for melanoma across all branches of
service. We feel the DoD can allocate resources to research and treatment for other
ailments that have been associated with deployment and can affectively rule out
melanoma as a cause for concern for deploying Soldiers. However, military members
serving in a combat role, regardless of deployment history, need to be educated and
trained on the hazards of occupational sun exposure. These service members need to be
given the proper guidance to protect, identify, and mitigate the caustic effects of
melanoma.

16

Table 1.1 Army Public Health Center, Edgewood, MD. Melanoma, Matched CaseControl Study 2001-2015
Variable

N (%) Avg (SD) Cases (1363) Controls (13,630)

P-Value

Matched Variables
Age (±5yrs)

34.6 (8.5) 35.3 (8.7) 34.6 (8.5)

0.002

Sex
Female

2244 (15)

204 (15.0)

2040 (15.0)

Male

12,749 (85) 1159 (85.0) 11590 (85.0)

1.00

Service
Army

4807 (32.0)

437 (32.1)

4370 (32.1)

Navy

3707 (24.7)

337 (24.7)

3370 (24.7)

Air Force

5148 (34.3) 468 (34.3)

4680 (34.3)

Marines

1331 (8.9)

1210 (8.9)

Time in Military (yrs.) 13.3 (7.9)
Year of Match

121 (8.9)

13.64 (8.0) 13.21 (7.9)

2008.7 (3.9) 2008.7 (3.9)

1.00

0.053

2008.7 (3.9)

1.00

<.0001

Covariates
Race
White

9741 (65)

1240 (91.0)

8501 (62.4)

Asian/PI

557 (3.7)

12 (0.88)

545 (4.0)

Black

2340 (15.6)

9 (0.66)

2331 (17.1)

Hispanic

1420 (9.5)

36 (2.6)

1384 (10.2)
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Am. Indian

156 (1.0)

11 (0.81)

145 (1.1)

Other

365 (2.4)

11 (0.81)

354 (2.6)

Unknown

414 (2.8) 44 (3.2)

370 (2.7)

Smoker
No

12350 (82.37) 1105 (81.1)

11,245 (82.5)

Yes

2643 (17.63)

258 (18.9)

2385 (17.5)

No

12313 (82)

981 (72)

11,332 (83)

Yes

2680 (18)

382 (28)

25.5 (13.2)

24.6 (13.3) 25.6 (13.2)

0.176

Cancer Screen

Immunizations

<0.001

2298 (17)
0.007

Special Forces
No
Yes

13,851 (92.4) 1247 (91.5)
1142 (7.6)

116 (8.5)

12604 (92.5)

0.186

1026 (7.5)

Combat Occupation
No
Yes

14,197 (94.7) 1242 (91.1)
796 (5.3)

121 (8.9)

12955 (95.1)

<0.001

675 (4.9)

Year of Entry into Service 1995.5 (8.8) 1995.1 (8.95) 1995.6 (8.80)

0.093

Exposure Risk Factors
Deployed
No

7618 (50.8)

725 (53.2)

6893 (50.6)

Yes

7375 (49.2)

638 (46.8)

6737 (49.4)

18

0.038

Number of Deployments 0.84 (1.12) 0.81 (1.13)

0.85 (1.12)

0

7618 (50.8)

725 (53.2)

1

4149 (27.7)

353 (25.9) 3796 (27.9)

2

1917 (12.8)

177 (13.0)

1740 (12.8)

>2

1309 (8.7)

108 (7.9)

1201 (8.8)

0.260

6893 (50.6)
0.143

Deployed Time (days) 173.5 (265.8) 163.8 (258.4) 174.5 (266.6) 0.155
0

7618 (50.8)

725 (53.2)

6893 (50.6)

1 – 180

2265 (15.1)

189 (13.9)

2076 (15.2)

181 – 360

2512 (16.8)

223 (16.7)

2289 (16.8)

>360

2598 (17.3)

226 (16.6)

2372 (17.4)

Note. All variables are “0 years - Prior To Incident Encounter/Matching”
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0.203

Table 1.2 Active-Duty DoD Service Members. Melanoma Incidence-Density Matched
Case Control, years 2001-2015. Conditional Logistic Regression Unadjusted Odds Ratios
& 95% CI
Variable

Odds Ratios

95 % CI

P-value

Exposure Variables
Deployed (Y vs N)

0.88

0.77 - 0.99

0.038

Deployed Number
0

REF

1

0.87

2–9

0.89

0.75 - 0.99
0.75 - 1.05

0.047
0.169

Deployed Time(days)
0

REF

1 – 262
263 – 2439

0.89
0.82

0.77 - 1.03
0.72 - 1.01

0.610
0.211

Covariates
Combat Occ (Y vs N)

1.96

1.59 - 2.42

<.001

0.03

0.01 - 0.05

<.001

Race
White

REF

Black
Other
Smoker (N vs Y)

0.27

0.22 - 0.33
0.90

0.78 - 1.05
20

<.001
0.176

Special Forces (N vs Y)

0.87

0.71 - 1.07

0.186

0.78 – 1.16

0.636

Year of Entry into Service
1964 – 1988

REF

1989 – 1995

0.95

1996 – 2002

0.75

2002 – 2015

0.72

0.58 – 0.97
0.54 – 0.98

Note. All variables are “0 years - Prior To Incident Encounter/Matching”
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0.027
0.034

Table 1.3 Active-Duty DoD Service Members. Melanoma Incidence-Density Matched
Case Control, years 2001-2015. Conditional Logistic Regression Adjusted Odds Ratios &
95% CI
Variable

Odds Ratios

95 % CI

P-value

Exposure Variables
Deployed (Y vs N)

0.87

0.77 - 0.99

0.043

0.75 - 1.00

0.054

Deployed Number
0

REF

1

0.87

2-9

0.85

0.72 - 1.01

0.069

Deployed Time (days)
0

REF

1 – 262

0.92

0.79 - 1.07

0.274

263 – 2439

0.82

0.73 – 1.04

0.129

Covariates
Combat Occ (Y vs N)

1.46

1.17 - 1.81

<.001

Race/Ethnic
White

REF

Black

0.02

0.01 - 0.05

<.001

Other

0.27

0.22 - 0.33

<.001

Year of Entry into Service
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1964 – 1988

REF

1989 – 1995

0.93

0.76

1.14

0.500

1996 – 2002

0.77

0.59

1.01

0.055

2002 – 2015

0.69

0.50

0.94

0.019

All variables are “0 years - Prior To Incident Encounter/Matching”
All Exposure Variables were entered independent of one another with all covariates for
our final model.

Table 1.4 Risk for Diagnosis of Melanoma for Different Latency Periods From: 0, 1, 4,
Years. Unadjusted Matched Odds Ratios & 95% Confidence Intervals
Latency Years
Variable

0

Exposure:
Deployed Number

1

4

OR (95%CI)
0.96 (0.91-1.02)

0.98 (0.92-1.05)

0.94 (0.86-1.03)

Deployed Time (yrs.) 0.91 (0.83-1.01)

0.89 (0.80-0.99)

0.88 (0.76-1.02)

Deployed*

0.92 (0.81-1.05)

0.92 (0.78-1.07)

1.14 (1.01-1.30)

Covariates:
Combat Occ*

0.51 (0.41-0.63) 0.49 (0.40-0.62)

0.51 (0.41-0.65)

Smoker*

0.90 (0.78-1.05)

1.06 (0.9-1.25)

1.04 (0.84-1.29)

Special Forces*

0.87 (0.71-1.07)

0.89 (0.72-1.1)

0.79 (0.62-1.0)

*All categorical variables are No vs Yes
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Table 1.5 A Melanoma Incidence-Density Matched Case Control Study - Conditional
Logistic Regression - Combat by Times Deployed and Number of Days Deployed
Variable

Odds

95% CI

p-value

Ratio
Odds Ratios of Combat Cases
by Number of Deployments
Number Times Deployed
0

1.47

1.05 – 2.08

0.027

1

1.46

0.91 – 2.35

0.093

2

1.30

0.60 – 2.80

0.680

>2

1.96

0.64 – 5.96

0.460

0

1.47

1.05 – 2.08

0.027

1-180

2.88

0.84 – 9.87

0.093

181-360

1.16

0.58 – 2.32

0.680

>360

1.21

0.72 – 2.02

0.460

Odds Ratios of Combat Cases
by Number of Days in
Deployments
Time in Deployment (days)

*Models adjusted for race and time of entry into the service.
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Table 1.6 A Melanoma Incidence-Density Matched Case Control Study - Conditional
Logistic Regression - Combat by Branch of Service
Case

Control

Odds Ratio

1.30

Army
Combat

61

365

Non-Combat

376

4005
Navy

Combat

46

228

Non-Combat

291

3142

1.74

Marines
Combat

11

74

Non-Combat

110

1136
Air Force

Combat

3

Non-Combat

465

1.30

3.11
6
4672

*Models adjusted for race and time of entry into the service.
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Areas of Strategic Concern for Operation Enduring Freedom and Operation Iraqi
Freedom
Source: Contingency Tracking System (CTS) Deployment Demographic File
OEF - Afghanistan, Djibouti, Kyrgyzstan, Pakistan, Yemen, and the Philippines
OIF - Iraq, Kuwait, Jordan, and Qatar
Figure 1.1 Areas of Strategic Concern for Operation Enduring Freedom and Operation
Iraqi Freedom
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CHAPTER 2. LUNG CANCER
Abstract
Purpose The objective of this study was to examine the associations between a history of
deployment in support of Operation Enduring Freedom (OEF) or Operation Iraqi
Freedom (OIF), from 2001 through 2015, and the risk of developing lung cancer.
Methods An incidence-density matched case-control study was conducted with 189
incident lung cancer cases and 1,890 matched controls. Individuals in the Armed Forces
serving in one of the main branches of service who developed lung cancer between 2001
to 2015 were considered cases. For each case, ten controls were drawn at random from all
individuals in the same Branch of Service who were at-risk of lung cancer during the
same period as the case but did not develop the outcome. Conditional logistic regression
was used to evaluate associations between three different deployment metrics (ever vs
never deployed, number of deployments, and cumulative time deployed) and lung cancer
risk, adjusted for epidemiologically relevant covariates, in three separate models.
Statistical interactions between smoking and the deployment metrics were assessed by
comparing conditional logistic regression models with and without a multiplicative
interaction term.
Results Analyses of the three-deployment metrics, adjusted for age and smoking status,
indicated that being deployed is protective against developing lung cancer (ORs 0.64 to
0.73), but no associations were statistically significant (respective p-values: >0.05).
Having a combat occupation was found to be significantly protective against developing
lung cancer (OR=0.43; 95% CI 0.18,0.99; p=0.048). Significant interactions were
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observed between smoking status and having ever deployed, while adjusting for combat
occupation (P = 0.044). Additionally, we when stratified by smoking status, smokers who
had not deployed had a statistically significant increased risk for lung cancer (OR = 2.27,
95%CI 1.39, 3.71). Non-smokers showed no association with lung cancer based on
deployment status (OR = 1.16, 95%CI 0.78, 1.73).
Conclusion These findings suggest that environmental exposures while deployed in
support of OIF/OEF were not associated with subsequent lung cancer development. We
recommend that the Defense Health Agency Campaign Plan emphasize smoking
cessation across the Department of Defense, regardless of deployment status.

Introduction
Causes of Cancer
Lung cancer is a disease characterized by genetic, molecular, and biological
malformations which develop into a carcinogenesis of lung epithelium (47). Carcinoma
of the lung is divided into two separate categories: Non-small-cell lung cancer (NSCLC)
which constitutes approximately eighty percent of all lung cancer cases; and small cell
carcinoma (SCLC) which is the remaining twenty percent (48). Etiological factors of
lung cancer have been attributed to a number of environmental exposures: air pollution,
smoke, radon, asbestos and most notably smoking of tobacco products (49).
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Lung Cancer in the Military
SCLC and NCLC contribute to over 25% of all cancer deaths in the US (50-52).
Similarly, lung cancer in the military is the leading cause of cancer-related deaths, with
NSCLC attributing to 87% of these cases (53). Compared to the US population, service
members (SM) across all branches were shown to have statistically lower incidence rates
(54). Additionally, SM are more likely to have cancer detected earlier, are 25% more
likely to receive a diagnosis in general, and higher survival rates than their civilian
counterparts (53,55-56). Contrary to the US population, there are no disparities in lung
cancer mortality by socioeconomic status nor race/ethnicity among SM (56-57). Previous
studies have attributed this to: mandatory periodic health assessments; active and fitnessoriented lifestyle; strict physical fitness and height/weight standards evaluated
periodically; and a large push towards smoking cessation from the Surgeon General (5657).
Exposures for Cancer in the Military
US military personnel with prolonged deployments in the Persian Gulf and
Afghanistan, were often exposed to sand, dust, burn-pits, and other air pollutants.
Pollutants, such as particle matter (PM) emissions, are a by-product of almost any
industrial complex. PM levels are substantially higher in Southwest Asia due to dust
storms, lax industry pollution standards, and others, such as: depleted uranium; oil well
fires; low-level nerve agents at Iraqi facilities; and radiation from nuclear weapons testing
(55,58). Exposure to carcinogenic chemicals for SMs who were deployed at high-risk
areas are often increased compared to their non-deployed counterparts. Polychlorinated
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biphenyl (PCBs), solvents trichloroethylene (TCE) and perchloroethylene (PCE) have
been identified as three such chemicals often in higher concentrations in areas of
deployment, compared to in the US (55). Ambient breathing air for SM who work
extensively outdoors, such as military police, infantry, and quarter master, have been
shown to be carcinogenic (59). Additional exposures for individuals deployed can be
attributed to short-term dust storms and motor vehicles disturbance of the desert floor
(58).
Other industrial exposures include asbestos which has been used in the
construction of older buildings and ships, across the entire Department of Defense (DoD)
(60). Service members who worked in shipyards, insulation work, demolition, carpentry,
mining and sometimes milling could have been exposed to harmful levels of asbestos.
The Department of Human Health Services (DHHS) and World Health Organization
(WHO) have documented that consistent occupational exposure to asbestos can cause
lung cancer (60).
Smoking is the leading cause of lung cancer across the globe (50). Though, since
2005, smoking in US population has been on a steady decline. Unfortunately, smoking
has been reported to be higher among military personnel compared to the US population.
Approximately 24% of active-duty personnel are currently identify as current smokers,
compared to 19% of the general population (61). The reasons for a greater smoking
prevalence in the military are unclear but may be related to work stress. The DoD
maintains active smoking cessation programs among all branches of service.
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Materials and Methods
Data source
A nested case-control study was conducted among active-duty personnel who
were serving in one of the Armed Forces branches: Army, Navy, Marines, or Air Force,
from 2001 through 2015. The data were ascertained from the Armed Forces Health
Surveillance Branch (AFHSB) who extracted it from the Defense Medical Surveillance
System (DMSS), and the DoD Automated Central Tumor Registry Database.
Deployment data came from the AFHSB, United States Army Special Operations
Command (USASOC)-Human Resources Command, Marine Corps Manpower, and
Reserve Affairs. Occupational and demographic data for all study subjects was
ascertained from DMDC (Defense Manpower Data Center) databases.
Case Ascertainment
Lung cancer cases were identified using ICD-9 diagnosis codes for cancer
selection and discharge codes, noted in the DoD inpatient and outpatient medical records
(DMSS). Additionally, ICD-03 codes were used from tumor registry data and pathology
reports. Diagnostic codes corresponding to notations of cancer in remission, relapse, or
metastatic were utilized to confirm cases, but were not used as the initial diagnosis of
cancer.
Cases were those who met one of the following inclusion criteria:
(1) Identified in the medical record and validated by the tumor registry data;
(2) Identified in the medical record and not validated using tumor registry data;
(3) Identified in the tumor registry, but not necessarily in the medical record data.
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An individual was considered an incident case only once per lifetime. Individuals with
diagnoses of prior cancers (regardless of type/location) in the medical record were
excluded from the study population, as were individuals within situ tumors. To assign
case status using DoD medical records, the AFHSB developed definitions for
surveillance purposes.
Primary cancers were defined as one hospitalization with any of the defining
diagnoses of the lung cancer in the primary diagnostic position or one hospitalization
with a V-code indicating a radiotherapy, chemotherapy, or immunotherapy treatment
procedure in the primary diagnostic position. For any case, the incidence date was
defined as the date of ‘-the first hospitalization-’ or outpatient medical encounter that
includes a defining diagnosis for lung cancer.
In primary analyses, cases were determined using cases defined using medical
records, without any validation from the registry and/or pathology reports. A second set
of analyses were restricted to cases identified in the medical record and validated by
either cancer registry data or pathology reports. A final set of analyses were restricted to
only those cases obtained from the tumor registries.
Control Ascertainment
Risk-set sampling was used to select controls. This involved longitudinal
sampling of controls from the population at risk of lung cancer at the time a case was
diagnosed. Risk sets were identified using DoD/DMDC demographic files and records.
Ten control subjects were randomly selected from each case’s corresponding risk sets as
of their diagnosis date. The controls in this study must have been at risk of being a case at
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the time of being selected. It was possible for a control (no history of cancer at the time
matched to a case) to later become a case. It was also possible that controls could be
selected as a control more than once at differing times, for other cases. Risk set sampling
enables the researcher to accommodate the possibility that the study population is
dynamic in that the individual may enter and leave the population during the risk interval.
Matching was done on age (±5 years), gender, branch of service, and time in service.
Study Design / Exposure Assessment
Once all cases and controls were identified, the DMDC deployment database was queried
using a roster of the entire study population (cancer cases and corresponding controls)
including personal identifiers.
The following deployment-related information was ascertained:
(1) Whether a participant ever deployed;
(2) Start and end date of each deployment.
Exposure status was abstracted for the five assumed latent periods: 0, 1, 4, 8, and 10
years. This was done to account for exposures which may not have been contributed to
the risk of developing lung cancer because the cancer process has already initiated.
Methods for evaluating latency were performed similarly to previous cancer studies (62).
Covariate information evaluated as potential confounders, independent risk
factors, and effect modifiers (not including the matched variables) included: race;
smoking status (self-reported current smoker versus currently not a smoker); receiving
cancer screening (yes versus no); number of immunizations; and year of entry into the
service.
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The major independent risk factor of concern was deployment. Deployment status
could change since this measure of potential exposure assessment applied at the time of
sampling for both cases and controls, based on the assumed latency period.
Statistical Analysis
The association between deployment (and other potential explanatory variables)
and odds of cancer diagnosis was assessed using multivariable conditional logistic
regression. Risk comparison between cases and controls were presented as odds ratios
(ORs) and 95% confidence intervals (95% CI) with associated p-values. The linearity of
the exposure-responses between log odds of cancer and continuously distributed variables
were examined by creating indicator variables based on selected categories. The risk
variable, ‘number of deployments’ was categorized into three categories: 0 deployments;
1 deployment, 2-9 deployments. Total time deployed was also categorized into three
categories: 0 days deployed; less than or equal to 365 days deployed, and greater than
365 days deployed. Wald test p-values less than 0.05 were considered evidence of
statistical significance.
Descriptive statistics are presented as frequencies and percentages for categorical
variables and means with standard deviations for continuous variables. Differences in
categorical characteristics between cancer cases and controls were assessed using Chisquare tests of two independent proportions and univariate logistic regression. Student’s t
test, and univariate logistic regression were used to identify differences in continuous
variables between cases and controls. All continuous variables, regardless of distribution,
were evaluated using parametric tests due to the robust sample size. The database noted
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seven racial and ethnic categories for the cases and controls, however due to low number
of participants in certain categories the following three categories were used to analyze
the association between race and lung cancer risk: non-Hispanic white (ref), Black, and
all other.
Unadjusted conditional logistic regression models were based on predicting the
conditional log odds of cancer diagnosis by our three main variables for exposure.
Additionally, we evaluated odds ratios by other potential confounding variables such as
race, smoking history (No vs Yes), and special forces operations personnel (No vs Yes)
combat occupation (No vs Yes) and year entered the Armed Forces active-duty status.
Effect modification and interactions between smoking and the deployment
exposures were also evaluated adjusting for risk variables. A Cochran-Mantel-Haenszel
stratified analysis was used to evaluate lung cancer risk by deployment by categories of
smoking status.
To examine the influence of different latency period assumptions on the estimated
effects of deployment on lung cancer odds, we re-ran unadjusted and adjusted conditional
logistic regression models for each exposure variable under each assumed latency. All
categorical variables were binary, and the two exposure variables for number of
deployments and cumulative years deployed were each evaluated as continuous.
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Results
Descriptive Statistics
Participant Characteristics

The characteristics of the 189 incident lung cancer cases and 1,890 matched
controls are reported in Table 2.1. The average age of cases was 39.2 years which is well
below the average age of 70 for lung cancer cases in the US general population (63).
Although the controls were age-matched to the cases (±5 years), the cases tended to be
older, with 55% of the cases above 40 years old while only 48% of the controls were
above age 40. The average ages of the controls were close to the average of the controls
with a mean of 38.2 years, but the variance about these means was wide with a standard
deviation of 9.6 for the cases and 9.1 for the controls. Cases were mostly men (84%) and
non-Hispanic white (64%). The prevalence of current smoking was 44% among the cases
and 16% among the controls. It is important to note that 56% of the cases were nonsmokers, but this group could have included former smokers. No significant associations
were observed between the deployment metrics and lung cancer odds, but controls tended
to be somewhat more commonly deployed than cases. However, a significantly greater
proportion of controls (8.6%) had served in a combat role than had cases (3.2%)
(p=0.009).
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Unadjusted Conditional Logistic Regression
Deployment Status and Cigarette Smoking on Lung Cancer

The results of unadjusted conditional logistic regression of the deployment
variables, and covariates of interest are presented in Table 2.2. The controls were more
commonly deployed than the cases. Analysis of the selected exposure metrics indicates
that being deployed was slightly protective for developing lung cancer with ORs ranging
from 0.71 to 0.75, but none of the comparisons were statistically significant (p>0.05).
Individuals serving in a combat occupation had a significantly decreased odds of being
diagnosed with lung cancer compared to those who did not serve in a combat occupation
(OR=0.34, 95%CI 0.15-0.78; p=0.011).
Table 2.3 presents the results of the conditional logistic regression analysis for the
deployment, Special Forces, and combat status variables adjusted for age and smoking
status. There results yield essentially the same interpretation as the unadjusted results.
SMs who were deployed, compared to non-deployed, had a somewhat lower odds of
developing lung cancer (ORs ranging from 0.64 to 0.73), but none of the comparisons
were statistically significant. No significant association was found between serving in a
Special Forces unit and odds for developing lung cancer (OR=0.86; 95%CI 0.49,1.50;
p=0.589). Serving in a combat unit however was significantly protective (OR=0.43,
p=0.048).
Smoking was the major risk factor for developing lung cancer with 44% of the
cases being current smokers while only 16% of the controls were smokers (OR=4.41,
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95%CI 3.18-6.13; p<0.001). Smoking was also an important confounding variable with
SMs who were deployed being somewhat more commonly smokers than those not
deployed (Table 2.4). It is important to note however, that SMs in combat roles were
significantly less likely to be smokers than SMs in non-combat units (OR=0.27,
p<0.001). Smoking also appeared to be a potential effect modifying variable as the ORs
for lung cancer between cases and controls varied markedly between SMs who were
deployed or served in a combat role compared to SMs who were not deployed or served
in a combat role (Table 2.5). Only 8.5% of the cases and 7.4% of the controls served in
Special Forces units, and no statistically significant association was observed between
being in Special Forces and the odds of developing lung cancer, or odds of being a
smoker.
Statistical interactions between smoking and the exposure metrics were also
assessed by comparing conditional logistic regression models with and without a
multiplicative interaction term. Significant interactions were observed between current
smoking status (No vs Yes) and deployed (ever/never) (P = 0.044) (Table 2.5). Nonsmokers, regardless of deployment status, had a decreased odds of being diagnosed with
lung cancer compared to smokers. Non-smokers versus smokers who deployed had an
OR=0.33 (95%CI:0.21-0.54) and non-smokers versus smokers, who had not deployed
had an OR=0.17 (95%CI:0.11-0.27). When analyzing SM who had deployed versus nondeployed, the non-smokers showed no significant association with risk of lung cancer,
OR=0.91 (95%CI:0.59-1.41); however, when analyzing those who had deployed vs nondeployed amongst smokers, those smokers who deployed had a decrease in odds of lung
cancer OR=0.47 (95%CI: 0.27-0.80). Demonstrating a protective status for individuals
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who deployed, consistent with our unadjusted and adjusted ORs for the deployment
variable.
When stratified by combinations of deployment (No vs Yes) and smoking status
(No vs Yes) the difference in ORs for lung cancer by deployment exposure was
significantly greater in smokers than non-smokers, OR=2.27 (95%CI:1.39, 3.71),
OR=1.16 (95%CI:0.78, 1.73), p-value for the Breslow-Day test (0.039). The three CMH
statistics test the same Ho, all conditional odds ratios are equal to 1, we reject the null
with p-values of 0.0083 (Table 2.6).
With respect to latency periods, we evaluated zero, one, four, eight, and ten years
from date of diagnosis (Table 2.7). Using an unadjusted conditional logistic regression,
we evaluated all exposure variables and the two covariates we felt were impactful to the
study. The exposure variables showed no association to risk of lung cancer with latency.
Both combat occupation and smoking showed an association with risk of lung cancer.
Those individuals serving in a service and support role, compared to those serving in a
combat occupation, had an approximate 300% increase in the odds of lung cancer
regardless of latency year. Non-smokers compared to smokers, for years 0, 1, and 4, had
a 77%, 59%, and 63% decrease in odds of lung cancer, respectively.

Discussion
The primary goal of this study was to evaluate any association with deployment
and lung cancer. We found that being deployed, whether adjusted or not for our primary
covariates, was protective against lung cancer though not statistically significant. Reasons
for this finding may be that SMs who are deployed tend to be healthier in general and
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lead to stronger, more active lifestyles than SMs who have never deployed (64). Exercise
is associated with a decreased risk of lung cancer (64-66). For SM who were nondeployed, they may become more complacent with their physical fitness compared to
those deployed. Deployed SM may also represent a selected-survivor population who are
in general healthier and more robust than personnel who are not deployed. We found that
deployed personnel had a somewhat higher prevalence of being cigarette smokers.
Smoking is clearly the number one cause of lung cancer across the globe (50). In
this study, we found that a history of deployment was associated with smoking. While not
statistically significant, SM who had deployed had a greater odds of being current
cigarette smokers. Long-term, this could influence the SM’s risk of lung cancer (67-68).
Studies from the Millennium Cohort identified deployment was associated with smoking
initiation and recidivism, especially with prolonged deployments, multiple deployments,
or combat exposures (69). We also discovered that deployment status and smoking
multiplicative interaction was statistically significant (p = 0.044); with the difference in
ORs for lung cancer according to deployment much greater in smokers than in nonsmokers. This trend was pronounced when we adjusted for combat occupation. We
recommend the most important risk reduction strategy towards lung cancer risk would be
smoking cessation across the entire DoD. Policies are already in place to help individuals
with post-deployment post-traumatic stress disorder (PTSD) which has been linked to
increase in tobacco and alcohol usage (70-71). In an effort “Toward A Tobacco-Free
Military Population” (72) the idea of establishing a tobacco-free military has been
initiated in the past, but has never has any substantial success (72). Through policy
changes, the DoD hopes to restrict and deter new tobacco users. Additionally, most US
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Military installations are tobacco-free, to include vaping and any form of cannabidiol
products. With an emphasis on physical, spiritual, and mental health the Army as well as
other branches of service are enacting comprehensive tobacco-control programs (72).
The ages of our cohort were 18 to 65 years old, based upon the standards for all
Active-Duty US military members. The average age for our cases was approximately 39
years old, approximately 30 years younger than the average age of lung cancer patients in
the general U.S. population (61). We believe we are simply dealing with a subset of
people who are diagnosed with lung cancer at a young age, in a very young cohort. One
of the limitations of a nested case-control study is you get the cases you get, and they
may not reflect all the cases that will eventually become manifest in this cohort. We are
not able to yet study all the lung cancer cases that might eventually occur in this cohort as
it ages. It is plausible, that someday having been deployed may actually present in the
data as a risk factor for developing cancer.
SM working in a combat role had dramatically decreased risk of lung cancer odds
compared to SM in other roles, in both unadjusted and adjusted analyses. Based on
military standards, combat occupation personnel participate in additional training and
exercise programs, necessitated by their job duties and descriptions (73-76). Additionally,
sedentary jobs have been associated with an increased risk of lung cancer and could be
attribute to our findings (77). Brenner et al, showed higher levels of physical activity are
consistently associated with 25% lower risk of developing lung cancer in prospective
studies (78). Lastly, a study has shown that SM in a combat unit, had the second lowest
rates of current and past smoker compared to those in the service & support, with health
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care/medical service corps having the lowest (66). The SM likely also represent an
especially healthy, robust selected population.
Socioeconomic status (SES), across the globe, has been associated with lung
cancer (79). People living in lower SES tertiles have been shown to have an increased
risk in lung cancer compared to their higher SES counterparts (80-81). The increased risk
has been attributed to quality of life, race, and access to care (82-84). However, in the
military SES has no relation to cancer risk or survival (56-57). We evaluated the
association between race and lung cancer in our study, and our results are consistent with
other studies that race within the Military Services shows no association with risk of lung
cancer. Lung cancer risk associated with SES such as access to care, accessible cessation
education, and screening are all but eliminated in Military Services (56-57).
After our analysis for latency (0, 1, 4 years) and its association with odds of
diagnosis for lung cancer, we found that deployment and those individuals in a combat
occupation were consistently found to be protective. These results are consistent with our
previous findings in our adjusted conditional logistic regression models, where latency
was not evaluated.
In conclusion, our results show, protective associations between those who had
deployed versus non-deployed and odds of lung cancer, though none significant.
Smoking, as with a multitude of previous studies, is strongly associated with an increased
risk of lung cancer. This study found an interactive association between smoking and
deployment. When stratified by smoking, individuals who were smokers and nondeployed, had a drastic increase in risk for lung cancer. Further insight is needed as to the
etiology, both physically and mentally with smoking and deployments, as it pertains to
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risk of lung cancer. A major limitation in this study was the lack of information on the
SM’s history of amount and duration of smoking. It is important to know how
deployment may have affected the amount of smoking while one was deployed or nondeployed. Although we know the time period and duration of service for the cases and
controls, we do not know specifically when or where the SM were deployed. Additional
limitations include potential inconsistencies with the diagnoses for lung cancer, and a
relatively young cohort who could potentially develop lung cancer later in life.
While the study suffered from these limitations, the analyses consistently showed
there was no evidence that being deployed increased SM’s risk of developing lung
cancer. In fact, being deployed displayed a somewhat protective factor, and serving in a
combat role was especially protective. Based upon our findings we would recommend to
the DHA Campaign Plan to consider further funding into smoking cessation across the
DoD and reallocate research and resources away from lung cancer as a potential threat
from overseas deployment.
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Table 2.1 Army Public Health Center, Edgewood, MD. Lung Cancer, Matched CaseControl Study 2001-2015
Variable

N (%) Avg (SD)

Cases (189)

Controls (1,890)

P-Value

Matched Variables
Age (±5yrs)

38.30 (9.1) 39.20 (9.6)

38.20 (9.1)

0.153

Sex
Female

341 (16.4)

Male

1738 (83.6)

31 (16.4)

310 (16.4)

1.00

158 (83.6) 1580 (83.6)

Service
Army

836 (40.2)

76 (40.2)

760 (40.2)

Navy

583 (28.0)

53 (28.0)

530 (28.0)

Air Force 484 (23.3)

44 (23.3)

440 (23.3)

Marines 176 (8.5)

16 (8.5)

160 (8.45)

Time in Military (yrs.)

16.02 (8.2) 16.47 (8.6) 15.98 (8.2)

Year of Match 2008 (4.0)

2008 (4.0)

2008 (4.0)

1.00

0.433
1.00

Covariates
Race
White

1292 (62.2)

120 (63.5)

Black

399 (19.2)

39 (20.6)

Asian/PI

101 (4.9)

8 (4.2)

93 (4.9)

Hispanic

162 (7.8)

7 (3.7)

155 (7.5)
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1172 (62.0)
360 (19.1)

0.116

Am. Indian

19 (0.9)

4 (2.1)

15 (0.8)

Other

48 (2.3)

3 (1.6)

45 (2.4)

Unknown

58 (2.8)

8 (4.2)

50 (2.7)

No

1691 (81.3)

106 (56.1)

1585 (83.9)

Yes

388 (18.7)

83 (43.9)

305 (16.1)

No

1651 (79.4)

143 (75.7)

1508 (79.8)

Yes

428 (20.6)

46 (24.3)

382 (20.2)

Smoker
<.001

Cancer Screen

Immunizations

25.11 (13.8) 24 (14.4)

25.20 (13.8)

0.181

0.378

Special Forces
No

1923 (92.5)

Yes

156 (7.5)

173 (91.5)
16 (8.5)

1750 (92.6)

0.599

140 (7.4)

Combat Occupation
No

1910 (91.9)

183 (96.8)

Yes

169 (8)

6 (3.2)

1727 (91.4)

0.009

163 (8.6)

Exposure Risk Factors
Year of Entry into Service 1992 (9.4) 1991.7 (9.7) 1992.2 (9.3)
45

0.486

Deployed
No

1084 (52.1)

108 (57.1) 976 (51.6)

Yes

995 (47.9)

81 (42.9)

0.149

914 (48.4)

Number of Deployments
0

1084 (52.1)

108 (57.1)

976 (51.6)

1

556 (26.7)

45 (23.8)

511 (27.0)

2+

439 (21.1)

36 (19.1)

403 (21.3)

0

1084 (52.1)

108 (57.1)

976 (51.6)

1 to < 365

605 (29.1)

49 (25.9)

556 (29.4)

>365

390 (14.8)

32 (16.9)

358 (18.9)

0.352

Deployed Time (days)

Note: All variables are “0 years - Prior To Incident Encounter/Matching”
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0.352

Table 2.2 Active-Duty DoD Service Members. Lung Cancer Incidence-Density Matched
Case Control, years 2001-2015. Conditional Logistic Regression Unadjusted Odds Ratios
& 95% CI
Variable

Odds Ratios

95 % CI

P-value

Exposure Variables
Deployed (Y vs N)

0.74

0.52 - 1.05

0.094

Deployed Number
0

REF

1

0.75

0.51 - 1.11

0.149

2–8

0.72

0.45 - 1.16

0.176

Deployed Time (days)
0
1 to < 365
>365

REF
0.75

0.52 – 1.10
0.71

0.143

0.43 - 1.18

0.188

0.15 – 0.78

0.011

Covariates
Combat Occ (Y vs N)

0.34

Race
White

REF

Black

1.06

0.72 – 1.56

0.767

Other

0.82

0.54 – 1.24

0.348
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Smoker (N vs Y)

0.23

0.16 - 0.32

<.001

Special Forces (N vs Y)

0.86

0.49 - 1.50

0.589

Year of Entry into Service
1963 – 1988

REF

1989 – 1995

0.95

0.58 – 1.56

0.841

1996 – 2002

0.74

0.37 – 1.45

0.376

2003 – 2015

0.88

0.40 – 1.98

0.755

All variables are “0 years - Prior To Incident Encounter/Matching”
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Table 2.3. Active-Duty DoD Service Members. Lung Cancer Incidence-Density
Matched Case Control, years 2001-2015. Conditional Logistic Regression Adjusted Odds
Ratios & 95% CI
Exposure Variables
Variables

OR

95% CI

P-value

Deployed (Y vs N)

0.70

(0.48 - 1.00)

0.05

Deployed Number
0

REF

1

0.72

(0.48 - 1.07)

0.50

2-8

0.67

(0.41 - 1.07)

0.28

Deployed Time (days)
0

REF

1 to <365

0.73

(0.49 – 1.08)

0.114

>365

0.64

(0.42 - 1.19)

0.102

Covariates
Combat Occup (Y vs N)

0.43

(0.18 – 0.99)

0.048

Smoker (N vs Y)

0.23

(0.17 - 0.33)

0.001

All variables are “0 years - Prior To Incident Encounter/Matching”
All Exposure Variables were entered independent of one another with all covariates for
our final model.
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Table 2.4 Smoking Status by Exposure Metrics - Incidence-Density Matched Case
Control Study - Conditional Logistic Regression
Variable

Odds Ratio

95% CI

p-value

Exposure Variables Applied One at a Time while Adjusted for Covariates
Ever Deployed*
No

1.00

Ref

---

Yes

1.20

0.91 – 1.57

0.194

0

1.00

Ref

---

1

1.17

0.87 – 1.58

0.301

≥2

1.24

0.89 – 1.73

0.211

0

1.00

Ref

---

≤365

1.16

0.87 – 1.56

0.312

>365

1.27

0.89 – 1.82

0.187

No

1.00

Ref

---

Yes

0.89

0.58 – 1.36

0.586

No

1.00

Ref

---

Yes

0.27

0.14 – 0.50

<0.001

Number Times Deployed*

Time in Deployment (days)*

Served in Special Forces*

Served in a Combat Role*

*Adjusted by age categories.
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Table 2.5 Active-Duty DoD Service Members. Lung Cancer Incidence-Density Matched
Case Control, Years 2001-2015. Conditional Logistic Regression Adjusted Odds Ratios
& 95% CI, with Interaction Terms
Variable

OR

95%CI

Combat Occupation

2.27

0.97-5.30

Deployed (Y) * Smoker (N)

P-value
0.058
0.044

1. Non-Smoker vs Smoker & Deployed

0.33

2. Non-Smoker vs Smoker & Non-Deployed

0.17

0.11-0.27

3. Deployed vs Non-Deployed & Non-Smoker

0.91

0.59-1.41

4. Deployed vs Non-Deployed & Smoker

0.47

0.27-0.80
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0.21-0.54

Table 2.6 Smokers vs Non-Smokers by Deployment for Lung Cancer
Cochran-Mantel-Haenszel Stratified Analysis.
Smokers
Case

Non - Smokers

Control Total

Case

Control Total

Non-Deployed 46

108

154

Non-Deployed

62

868

Deployed

37

197

234

Deployed

44

717

761

Total

83

305

388

Total

106

1585

1691

OR 2.27 (1.39, 3.71)

930

OR 1.16 (0.78, 1.73)

Breslow-Day Test for Homogeneity of Odds Ratios
Chi-Square

4.28

DF

1

Pr > Chisq

0.039

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)
Statistic

Alternative Hypothesis

DF

Value

Prob

1

Nonzero Correlation

1

6.98

0.0083

2

Row Mean Scores Diff

1

6.98

0.0083

3

General Association

1

6.98

0.0083
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Table 2.7 Risk for Diagnosis of Lung Cancer for Different Latency Periods From: 0, 1, 4
Years. Matched Odds Ratios & 95% Confidence Intervals
Latency Years
Variable

0

1

4

0.95 (0.81-1.12)

1.02 (0.85-1.21)

0.96 (0.75-1.23)

Deployed Time (yrs.) 0.90 (0.70-1.17)

0.94 (0.71-1.23)

1.04 (0.72-1.51)

Deployed (Y vs N)

0.74 (0.52-1.05)

0.87 (0.60-1.26)

1.00 (0.65-1.56)

Combat Occ*

2.98 (1.29-6.88)

2.81 (1.22-6.50)

2.65 (1.14-6.15)

Smoker*

0.23 (0.16-0.32)

0.41 (0.29-0.59)

0.37 (0.23-0.58)

Deployed Number

*Categorical variables are No vs Yes
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CHAPTER 3. COMPARING INCIDENCE OF MELANOMA AND LUNG CANCER
IN THE US MILITARY, BY BRANCH OF SERVICE FOR YEARS 2001–2015
Abstract
Purpose To examine associations between the different branches of U.S. military service
and years of service between 2002 through 2015, for melanoma and lung cancer
incidence.
Methods Melanoma and lung cancer incidence rates from 2002 to 2015, among activeduty military personnel were compared using a Poisson Regression Analysis. Data were
obtained from the Defense Manpower Data Center, Defense Medical Surveillance
System, and the DoD Automated Central Tumor Registry Database.
Results Melanoma crude rates were higher for all other branches of service compared to
the Marines; the cancer incidence rates (per 100,000 person-years) were 4.6 for Marines,
9.89 for Air Force, 7.1 for Navy, and 6.05 for the Army. Additionally, the incidence rate
ratios (IRR) were significantly higher for all other branches compared to the Marines:
2.16 for Air Force; 1.55 for Navy; and 1.32 for Army. Lung cancer crude incidence rates
were lowest for the Marines amongst all branches of service. Additionally, lung cancer
IRRs were marginally higher for the Navy (IRR 1.84, CI: 1.01, 3.37, p-value 0.049)
compared to the Marines. Melanoma incidence increased 18.6%, from 2002-2008 to
2009-2015 for the entire Department of Defense. Army melanoma incidence rates
increased from 2002 to 2015, with a significant test for linear trend (p= 0.0009).
Conclusion These results are consistent with previous studies, showing the Air Force at
an increased risk for melanoma due to ionized radiation exposure. Further studies of risk
factors for melanoma in the military are needed to explain the rising rates from 200254

2008 to 2009-2015. While melanoma rates for the Army increased significantly from
2002 – 2014, they dropped off in 2015, and further analysis could show a downward
trend.

Keywords:

Introduction
Cancer has been studied extensively in the U.S. military, impart due to the access
and availability of medical records and registries. However, few studies have
demonstrated a relationship between cancer incidence and the different branches of
service. The goal of this study is to examine associations between the different branches
of the U.S. military (Army, Navy, Air Force, Marines) with melanoma and lung cancer
incidence between the years of 2002 through 2015.
Melanoma
Occupational sun exposure for military members has been documented as a risk
factor for melanoma and non-melanoma skin cancers (85). Previous work has shown that
early intervention and screening could play a pivotal role in the treatment and prevention
melanoma (86). The U.S. military has emphasized treating and screening high-risk
populations, to mitigate the risk of skin cancer among service members (87). Examples of
these efforts include banning of tanning beds and wide-spread communication campaigns
emphasizing the importance of hydration and applying sunscreen while performing work
and or recreational activities outdoors (87).
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The U.S. military mandates for all individuals to apply sunscreen and take other
protective measures against harmful UV rays (88). However, according to a survey of
Soldiers deployed in specific combat zones, less than 30% reported regular sunscreen
use, and were unprotected from harmful UV rays at least 70% of the time during their
normal work duties (89). Lack of adherence could be attributed to service members who
actively engage obstacles with an extreme amount of personal protective equipment, and
view applying sunscreen as a non-essential (89).
Apart from harmful UV rays, radiation exposure has been attributed to increased
risk for melanoma. In fact, the VA states that most cancers associated with military
service result from radiation exposure (90). Military personnel that work near nuclear
reactors, medical facilities, nuclear weapons, manufacturing and construction, security
operations, and air transport operations, are all susceptible to high levels of ionizing
radiation (91-93). Previous studies show ionizing radiation as a hazard for all military
personnel for developing melanoma cancer. One study reported the Air Force and Navy
to have a higher incidence of melanoma compared to the other services, with unadjusted
incidence rates for melanoma around 2.45 per 10,000 person-years (91-93). One
suspected etiological risk factor for the increased melanoma incidence was cosmic
ionizing radiation exposure, which is directly correlated with increasing in altitude.
Therefore, Soldiers with aviation-specific occupations may have increased exposure
compared to ground forces (94-95).
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Lung Cancer in the Military
Small cell lung cancer (SCLC) and Non-small cell lung cancer (NCLC) contribute
to over 25% of all cancer deaths in the US (96-98). Similarly, lung cancer in the military
is the leading cause of cancer-related deaths, with NSCLC attributing to 87% of these
cases (99). However, compared to the US population, service members (SM) across all
branches were shown to have statistically lower incidence rates (100). Additionally, SM
compared to their civilian counter parts have earlier detection, are 25% more likely to
receive a diagnosis, and higher survival rates (99, 101-102). Contrary to the US
population, there are no disparities by socioeconomic status nor race/ethnicity groups for
survival from lung cancer within the U.S. military (102-103). Previous studies suggest
these finding results from a combination of mandatory periodic health assessments, an
active and fitness-oriented lifestyle, strict physical fitness and height/weight standards
which are evaluated periodically, and access to smoking cessation programs as
encouraged by the Surgeon General (102-103).
Exposures for Cancer in the Military
US military personnel with prolonged deployments in the Persian Gulf and
Afghanistan, were often exposed to sand, dust, burn-pits, and other air pollutants.
Pollutants, such as particle matter (PM) emissions, are a by-product of almost any
industrial facility. PM levels are substantially higher in Southwest Asia, from dust
storms, lax industry pollution standards, and others, such as: depleted uranium; oil well
fires; low-level nerve agents at Iraqi facilities; and radiation from nuclear weapons testing
(101,104). Exposure to carcinogenic chemicals for SMs who were deployed at high-risk
57

areas are often increased compared to their branch counterparts stateside. Polychlorinated
biphenyl (PCBs), solvents trichloroethylene (TCE) and perchloroethylene (PCE) have
been identified as some of the hazardous chemicals often in higher concentrations in
areas of deployment, compared to US (101). PM in the atmosphere and breathing air for
SM who work extensively outdoors, such as military police, infantry, and quarter master,
have been shown to be carcinogenic (105). Additional exposures to PM for individuals
deployed can be attributed to short-term dust storms and motor vehicles disturbance of
the desert floor (104).
Other industrial exposures include asbestos which has been used in the
construction of older buildings and ships, across the entire Department of Defense (DoD)
(106). Service members who worked in shipyards, insulation work, demolition,
carpentry, mining and sometimes milling could have been exposed to harmful levels of
asbestos. The Department of Human Health Services (DHHS) and World Health
Organization (WHO) have documented that this level of exposure to asbestos can cause
lung cancer (106).
Though smoking in US population has been on a steady decline, it has been
reported to be higher among military personnel with approximately 24% of active-duty
personnel are currently smoking every day or regularly, compared to 19% of the general
population (107). The reasons for a greater smoking prevalence in the military are unclear
but may be related to work stress. The DoD maintains active smoking cessation programs
among all branches of service.

58

Materials and Methods
This study was restricted to active-duty military personnel with a diagnosis of
melanoma or lung cancer between 2002 to 2015. Populations estimates for each branch of
service were calculated as the average number of individuals enrolled over a calendar
year; the data were obtained from the Defense Manpower Data Center.
Cancer cases were identified using ICD-9 diagnosis codes for cancer selection
and discharge codes, noted in the DoD inpatient and outpatient medical records (DMSS).
Additionally, ICD-03 codes were used from tumor registry data and pathology reports.
Diagnostic codes corresponding to notations of cancer in remission, relapse, or metastatic
spread were utilized to confirm cases, but were not used as the initial diagnosis of cancer.
Cases were those who met one of the following inclusion criteria:
(1) Identified in the medical record and validated by the tumor registry data;
(2) Identified in the medical record and not validated using tumor registry data;
(3) Identified in the tumor registry, but not necessarily in the medical record data.
An individual was considered an incident case only once per lifetime. Individuals with
diagnoses of prior cancers (regardless of type/location) in the medical record were
excluded from the study population, as were individuals within situ tumors. To assign
case status using DoD medical records, the AFHSB developed definitions for
surveillance purposes.
Primary cancers were defined as one hospitalization with any of the defining
diagnoses of the lung cancer in the primary diagnostic position or one hospitalization
with a V-code indicating a radiotherapy, chemotherapy, or immunotherapy treatment
procedure in the primary diagnostic position. For any case, the incidence date was
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defined as the date of ‘-the first hospitalization-’ or outpatient medical encounter that
includes a defining diagnosis for lung cancer. In primary analyses, cases were determined
using cases defined using medical records, without any validation from the registry
and/or pathology reports.
A second set of analyses were restricted to cases identified in the medical record
and validated by either cancer registry data or pathology reports. A final set of analyses
were restricted to only those cases obtained from the tumor registries.
Incidence rates (per 100,000 person-years) and 95% confidence intervals (CIs)
were calculated, stratified by military branch of service and diagnosis year. Incidence
rates were calculated when there were at least 10 cases in each stratum. Incidence rate
ratios (IRRs) and 95% CIs were calculated using Poisson Regression, to compare rates
over time stratified by military branch of service. To correct for overdispersion when
calculating the IRRs and 95& CIs, we used a Negative Binomial for the melanoma
analysis and a Pearson Scale for the lung cancer analysis. Goodness-of-fit was estimated
by calculating p-values from the degrees of freedom (df) and values following a X2
distribution. All analyses were conducted using SAS software (version 9.3) and the 2sided significance level was set at P < 0.05.

Results
Melanoma incidence varied by military service branch (Table 3.2). Compared to
the Marines, those in the Navy, Army and Air Force had significantly higher rates.
Previous studies have shown the Air Force and Navy to have higher rates of melanoma,
based upon their exposure to ionizing radiation, and working in higher atmospheric
60

altitudes (108). Using Marines as our referent group, individuals serving in the Air Force
from 2002-2015, had 2.16 times the incident rate, with the Navy and Army demonstrating
increased rate ratios of 1.55 and 1.32, respectively.
Compared to the Marines, all other branches of service had higher incidence rates
of lung cancer, though only the Navy had a significantly increased rate ratio. Those
service members in the Navy had 1.84 times the incident rate compared to the Marines.
(Table 3.3)
From 2002-2008 to 2009-2015, melanoma incidence among all branches of
service increased significantly (Table 3.4). Though there was no evidence of a linear
trend and cancer incidence rates nearly peaking in 2014 and falling drastically in 2015.
During this same time period, melanoma cancer crude incidence rates in the U.S. Army
have steadily increased (Figure 1), following a linear trend of p-value 0.0009. Figures 1 –
4, show the crude incidence rates and kernel smoothing approach for melanoma for the
Army, Air Force and entire DoD. Contrary to the Army, the Air Force and DoD showed
no significant increase for melanoma rates.
Lung cancer incidence rates show no significant change from 2002-2008 to 20092015 (Table 3.4), additionally rates fluctuated between 2002-2015, showing no
significant change in linear trend.

Discussion
Our results showed significant differences in melanoma incidence rates among the
different branches of service in the U.S. Military from 2002 – 2015. The overall crude
melanoma incidence rates were significantly lower in the Marines than in the other three
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branches of service, with the Air Force having the highest. Lung cancer incidence rates
were not significantly different by service branch. Melanoma incidence rates increased
from 2002-2008 to 2009-2015 for the entire DOD, though lung cancer incidence rates
demonstrated no significant increase from the two year-groups studied.
Individuals serving in the Air Force and Navy have an increased risk for
melanoma, compared to the Army and Marines (108). Previous studies have found that
both military and civilian pilots have a higher risk for melanoma, compared to the general
population (109). Zhou and colleagues have attributed this finding to pilots are more
likely to be exposed to cosmic ionizing radiation (108). Though increased exposure to
cosmic ionizing radiation doesn’t tell the whole story, with less than four percent of
individuals serving in the Air Force are pilots (110). Other Air Force personnel are
exposed to known chemical carcinogens for melanoma (109). These chemicals include
fuel, jet engine exhaust, cabin air pollutants, and polychlorinated biphenyls (PCBs) (111).
All of these carcinogens have been identified on the surfaces, in component materials,
and equipment of older ships and vessels (112). Additionally, SM in the Air Force and
Navy have an increased cumulative sun exposure while serving on ships and vessels,
compared to Army and Marines.
Melanoma incidence rates significantly increased for the entire DOD from 20022008 to 2009-2015, though lung cancer incidence rates showed no significant increase.
While the incidence rates of melanoma increased over the course of time, this could be a
result from the sun exposure obtained from previous UV encounters. Studies have shown,
melanoma related to chronic UV exposure is more likely to be diagnosed later in life
(113). When melanoma incidence rates were further evaluated from 2002 to 2016, and
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stratified by branch of service, only the Army had statistically significance increase over
time (linear trend p-value = 0.0009) (Figure 1). The Gaussian kernel trend shows the
DOD and Air Force both had incidence rates increasing up until 2011-2012, then a
downward trend towards 2015 (Figures 2-3). Considering the latency with sun exposure
and the development of diagnosable melanoma, further research is necessary to
understand why the rates for both DOD and Air Force peaked around 2011-2012 and
have since declined (Figure 4). We recommend continuing to monitor melanoma
incidence rates in the U.S. military in order to determine if this trend continues and
incidence rates continue to decrease.
A limitation to this study is we have no demographic data for individuals serving
in the U.S. military. We were unable to evaluate age-adjusted rates and accurately
compare those to the general population. Additionally, we were unable to evaluate the
incidence rates based on sex or race.

Conclusion
From 2005 through 2014, melanoma was the most frequent cancer diagnosis in
the Active-Duty population (92). This study supports these findings related to melanoma,
though shows a favorable downward trend in incidence rates. Soldiers across the entire
DOD still need to be diligent protecting themselves from caustic UV rays, including
having adequate sunscreen access, sufficient emphasis on sun protections, and
prioritizing preventative care. While smoking rates in the Army have risen compared to
the general population, lung cancer incidence was not significantly associated with any
branch of service. This could be attributed to policies implemented by Veteran Affairs
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and Office of the Surgeon General for smoking cessation and educating on the harmful
effects of smokeless tobacco.
Table 3.1 Cancer Incidence Rates & 95% Cis for the US Military by Branch of Service,
Years 2002-2015. Ages 18-65, per 100,000 Person-years
Branch

Melanoma

Lung
Cancer

Population

Melanoma
(95% CI)

Lung Cancer
(95% CI)

Army

437

76

7228536

6.05 (5.45,
6.64)

1.05 (0.83,
1.27)

Navy

337

53

474035

Marines

121

16

2633295

Air Force

468

42

4732632

DoD

1363

189

19341495

7.10 (6.02,
8.08)
4.6 (3.59,
5.60)
9.89 (8.70,
11.08)
7.05 (6.45,
7.64)

1.11 (0.73,
1.51)
0.61 (0.30,
0.92)
0.89 (0.61,
1.17)
0.98 (0.83,
1.12)

Table 3.2 Incidence Rate of Melanoma Among U.S. Active-duty Military by Service
Branch. 2002-2015, Ages 18-65, per 100,000 Person-years
Branch

Count

Rate

IRR

Marines

121

4.6

REF

Air Force

468

9.89

2.16

(1.73, 2.69)

<.0001

Navy

337

7.1

1.55

(1.23, 1.95)

<.0001

Army

437

6.05

1.32

(1.05, 1.64)

<.0076

64

(95% CI)

P-value

Table 3.3 Rates of Lung Cancer Among U.S. Active-duty Military by Service Branch.
2002-2015, Ages 18-65, per 100,000 Person-years
Branch

Count

Rate

IRR

Marines

16

.061

REF

Navy

53

1.11

1.84

(1.00, 3.37)

0.049

Army

76

1.05

1.73

(0.96, 3.11)

0.067

Air Force

42

0.89

1.46

(.078, 2.73)

0.235

(95% CI)

P-value

Scale pearson value/DF = 1.18
Table 3.4 Incidence Rates of Melanoma and Lung Cancer Among U.S. Active-duty
Military by Years Studied. 2002-2015, Ages 18-64, per 100,000 Person-years
Cancer Site

Years

Melanoma

2002-2008

Lung

Count

Rate

IRR

626

6.45

REF

2009-2015

737

7.65

1.18

2002-2008

94

0.97

REF

0.99

1.02

2009-2015

65

(95% CI)

(1.03, 1.36)

(0.77, 1.35)

Army Melanoma Incidence Rates
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Figure 3.1 Figure Title
Legend: BLUE – Crude Rates; ORANGE – Kernel Smoothing; BLACK – Linear Trend
Linear trend analysis R2 = 0.614; p-value 0.0009; PE: 0.213 (0.106, 0.319)
Shapiro-Wilk p 0.1339 (rates are normally distributed)
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Figure 3.2 Figure Title
Legend: BLUE - Crude Rates; ORANGE - Kernel Smoothing; BLACK – Linear Trend
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Figure 3.3 Figure Title
Legend: BLUE - Crude Rates; ORANGE - Kernel Smoothing; BLACK - Linear Trend
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